HK1138502A1 - Combination of blys inhibition and/or april inhibition and immunosuppressants for treatment of autoimmune disease - Google Patents

Combination of blys inhibition and/or april inhibition and immunosuppressants for treatment of autoimmune disease

Info

Publication number
HK1138502A1
HK1138502A1 HK10103878.9A HK10103878A HK1138502A1 HK 1138502 A1 HK1138502 A1 HK 1138502A1 HK 10103878 A HK10103878 A HK 10103878A HK 1138502 A1 HK1138502 A1 HK 1138502A1
Authority
HK
Hong Kong
Prior art keywords
blys
inhibition
fusion protein
april
immunosuppressants
Prior art date
Application number
HK10103878.9A
Other languages
English (en)
Inventor
Jr Rafael A Ponce
Wayne J Wallis
Matthew S Holdren
Linda Zuckerman
Alisa M Littau
Kirk P Van Ness
Rossi Claudia Pena
Hans Otto Lennart Graffner
Original Assignee
Zymogenetics Inc
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc, Ares Trading Sa filed Critical Zymogenetics Inc
Publication of HK1138502A1 publication Critical patent/HK1138502A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
HK10103878.9A 2007-03-27 2010-04-21 Combination of blys inhibition and/or april inhibition and immunosuppressants for treatment of autoimmune disease HK1138502A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90836507P 2007-03-27 2007-03-27
PCT/US2008/058486 WO2008119042A2 (en) 2007-03-27 2008-03-27 Combination of blys inhibition and/or april inhibition and immunnosuppressants for treatment of autoimmune disease

Publications (1)

Publication Number Publication Date
HK1138502A1 true HK1138502A1 (en) 2010-08-27

Family

ID=39789276

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10103878.9A HK1138502A1 (en) 2007-03-27 2010-04-21 Combination of blys inhibition and/or april inhibition and immunosuppressants for treatment of autoimmune disease

Country Status (19)

Country Link
US (2) US8852591B2 (xx)
EP (1) EP2139517B1 (xx)
JP (1) JP5426531B2 (xx)
CN (1) CN101678106B (xx)
AU (1) AU2008230777B8 (xx)
CA (1) CA2681728C (xx)
DK (1) DK2139517T3 (xx)
EA (1) EA030313B1 (xx)
ES (1) ES2422479T3 (xx)
HK (1) HK1138502A1 (xx)
HR (1) HRP20130725T1 (xx)
IL (1) IL201114A (xx)
MX (1) MX2009010125A (xx)
PL (1) PL2139517T3 (xx)
PT (1) PT2139517E (xx)
RS (1) RS52888B (xx)
SI (1) SI2139517T1 (xx)
WO (1) WO2008119042A2 (xx)
ZA (1) ZA200906808B (xx)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8212004B2 (en) * 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US6812327B1 (en) * 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
WO2002002641A1 (en) * 2000-06-16 2002-01-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys
US7879328B2 (en) * 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
US9168286B2 (en) * 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
EA015860B1 (ru) * 2005-10-13 2011-12-30 Хьюман Дженом Сайенсиз, Инк. Способы лечения аутоиммунных заболеваний при использовании антагониста нейтрокина-альфа
WO2007123765A2 (en) * 2006-03-31 2007-11-01 Human Genome Sciences Inc. Neutrokine-alpha and neutrokine-alpha splice variant
EP2396035A4 (en) * 2009-02-12 2012-09-12 Human Genome Sciences Inc USE OF ANTAGONISTS OF PROTEIN STIMULATING LYMPHOCYTES B TO PROMOTE GRAFT TOLERANCE
US20130028897A1 (en) * 2009-04-27 2013-01-31 Ali Naji Methods for reducing the level of alloantibodies in a subject
EA201290837A1 (ru) * 2010-03-03 2013-05-30 Тева Фармасьютикал Индастриз Лтд. Лечение волчаночного нефрита с применением лаквинимода
CN101851278B (zh) * 2010-05-26 2013-03-13 石药集团中奇制药技术(石家庄)有限公司 B细胞激活因子拮抗剂及其制备方法与用途
US10017762B2 (en) 2010-11-24 2018-07-10 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Compositions and methods for treating or preventing lupus
US9657292B2 (en) 2010-11-24 2017-05-23 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Compositions and methods for treating or preventing lupus
CN102085367B (zh) * 2011-01-19 2012-08-22 烟台荣昌生物工程有限公司 优化的TACI-Fc融合蛋白用于制备治疗类风湿性关节炎药物的应用
JOP20140087B1 (ar) 2013-03-13 2021-08-17 Amgen Inc بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
CN103169966B (zh) * 2013-04-09 2015-04-01 中国人民解放军军事医学科学院基础医学研究所 一种治疗系统性红斑狼疮的药物组合物
NL2011406C2 (en) 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
CA2945486A1 (en) 2014-02-07 2015-08-13 Mcmaster University Trifunctional t cell-antigen coupler and methods and uses thereof
CN103965295B (zh) * 2014-04-18 2015-12-02 天津大学 BLyS拮抗肽、含TA-Fc融合蛋白基因的质粒及TA-Fc融合蛋白
CN103936833B (zh) * 2014-04-18 2016-02-10 天津大学 BLyS拮抗肽、含TC-Fc融合蛋白基因的质粒及TC-Fc融合蛋白
US10562954B2 (en) * 2014-05-12 2020-02-18 Shanghai Kanda Biotechnology Co., Ltd. Fusion protein inhibiting TACI-BAFF complex formation and preparation method therefor and use thereof
SI3380522T1 (sl) 2015-11-25 2024-02-29 Visterra, Inc. Molekule protitelesa proti APRIL in uporabe le-teh
EP3483181A4 (en) * 2016-07-06 2020-04-22 Shanghai Pharmaexplorer Co., Ltd. BLYS ANTIBODIES, PRODUCTION METHOD THEREFOR AND APPLICATION THEREOF
CA3078637A1 (en) 2017-10-12 2019-04-18 Mcmaster University T cell-antigen coupler with y182t mutation and methods and uses thereof
US11110123B2 (en) 2018-07-17 2021-09-07 Triumvira Immunologics Usa, Inc. T cell-antigen coupler with various construct optimizations
CA3086661C (en) * 2018-08-30 2022-04-12 The Governing Council Of The University Of Toronto Methods of treating an autoimmune disease
US20210401939A1 (en) * 2018-11-21 2021-12-30 The Governing Council Of The University Of Toronto Methods of treating an autoimmune disease
WO2020210670A1 (en) * 2019-04-12 2020-10-15 Biograph 55, Inc. Compositions and methods for cancer immunotherapy
US20230144779A1 (en) * 2019-12-20 2023-05-11 Vyome Therapeutics Inc. Formulations and method for treatment of inflammatory diseases
KR20220034742A (ko) * 2019-12-24 2022-03-18 레메젠 코, 리미티드 Taci-fc 융합 단백질 및 그 용도
PE20230494A1 (es) 2020-05-08 2023-03-23 Alpine Immune Sciences Inc Proteinas inmunomoduladoras inhibidoras de april y baff y metodos de uso de las mismas
WO2021243298A1 (en) * 2020-05-29 2021-12-02 Chinook Therapeutics, Inc. Methods of treating iga nephropathy with an april binding antibody
WO2021247512A1 (en) * 2020-06-02 2021-12-09 Merck Patent Gmbh Methods related to the treatment of iga nephropathy
US12016923B2 (en) 2021-06-01 2024-06-25 Triumvira Immunologics Usa, Inc. Claudin 18.2 T cell-antigen couplers and uses thereof
US11453723B1 (en) 2021-06-25 2022-09-27 Mcmaster University BCMA T cell-antigen couplers and uses thereof
JP2024510636A (ja) * 2021-08-10 2024-03-08 レメゲン シーオー.,エルティーディー. TACI-Fc融合タンパク質を用いたIgA腎症の治療方法
KR20240053675A (ko) * 2021-08-11 2024-04-24 악소 바이오파마슈티컬 인코포레이티드 sBCMA 변이체 및 이의 FC 융합 단백질을 이용한 IgA, IgM 및/또는 IgG의 생산 감소 방법
CA3236667A1 (en) * 2022-06-08 2023-12-14 Jianmin Fang Method for treating myasthenia gravis with taci-fc fusion protein
WO2024159715A1 (zh) * 2023-01-31 2024-08-08 荣昌生物制药(烟台)股份有限公司 用TACI-Fc融合蛋白治疗IgG4相关性疾病的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006201471B2 (en) * 2000-02-16 2009-07-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of TNF-related molecules
IL150755A0 (en) * 2000-02-16 2003-02-12 Genentech Inc Uses of agonists and antagonists to modulate activity of tnf-related molecules
KR101021124B1 (ko) * 2001-05-24 2011-03-14 지모제넥틱스, 인코포레이티드 Taci-면역글로불린 융합 단백질
AU2002322301A1 (en) * 2001-06-26 2003-03-03 Gene Logic, Inc. Methods for the diagnosis and treatment of cardiac tissue rejection
HUP0500992A3 (en) * 2001-08-03 2007-11-28 Genentech Inc Tacis and br3 polypeptides and uses thereof
CA2467521A1 (en) * 2001-11-16 2003-07-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys
US20050163775A1 (en) * 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
US20080181886A1 (en) * 2004-11-04 2008-07-31 Genentech, Inc. Polypeptides That Bind Baff And/Or April
BRPI0518432A2 (pt) 2004-11-17 2008-11-25 Angiogen Pharmaceuticals Pty L mÉtodo de modular o funcionamento de cÉlula b
AU2006281978A1 (en) * 2005-08-12 2007-02-22 Garvan Institute Of Medical Research Phrophylactic and/or therapeutic method for treatment of autoimmune disease
BRPI0711823A2 (pt) * 2006-05-15 2012-01-17 Ares Trading Sa métodos para tratamento de doenças auto-imunes com uma molécula de fusão taci-ig
EP2219675B1 (en) 2007-11-12 2013-10-23 Ares Trading S.A. Formulations for taci-immunoglobulin fusion proteins

Also Published As

Publication number Publication date
AU2008230777B8 (en) 2014-07-03
IL201114A (en) 2014-01-30
CA2681728C (en) 2015-12-22
CN101678106B (zh) 2013-06-05
ZA200906808B (en) 2011-10-26
JP5426531B2 (ja) 2014-02-26
AU2008230777B2 (en) 2014-02-27
MX2009010125A (es) 2010-02-17
US20150017164A1 (en) 2015-01-15
CN101678106A (zh) 2010-03-24
ES2422479T3 (es) 2013-09-11
WO2008119042A3 (en) 2009-04-30
EP2139517B1 (en) 2013-05-29
EA030313B1 (ru) 2018-07-31
CA2681728A1 (en) 2008-10-02
DK2139517T3 (da) 2013-08-26
HRP20130725T1 (xx) 2013-10-11
RS52888B (en) 2014-02-28
EP2139517A2 (en) 2010-01-06
AU2008230777A1 (en) 2008-10-02
SI2139517T1 (sl) 2013-09-30
IL201114A0 (en) 2010-05-17
US20080260737A1 (en) 2008-10-23
EA200901213A1 (ru) 2010-04-30
PL2139517T3 (pl) 2013-10-31
US8852591B2 (en) 2014-10-07
WO2008119042A2 (en) 2008-10-02
PT2139517E (pt) 2013-07-11
AU2008230777A8 (en) 2014-07-03
JP2010522767A (ja) 2010-07-08

Similar Documents

Publication Publication Date Title
HK1138502A1 (en) Combination of blys inhibition and/or april inhibition and immunosuppressants for treatment of autoimmune disease
WO2008064321A3 (en) Methods of treating chronic inflammatory diseases using a gm-csf antagonist
EA200701370A1 (ru) Способы получения стерильных суспензий или лиофилизатов труднорастворимых комплексов основных пептидов (варианты), стерильная суспензия и лиофилизат вышеназванных комплексов, фармацевтическая композиция, набор и лекарственное средство на их основе
WO2007027761A3 (en) Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease
HUE046110T2 (hu) Gyógyászati készítmények a rheumatoid arthritis betegségének és tüneteinek kezelésére
EP3552607A3 (en) Imidazopyrazine syk inhibitors
EP2331095A4 (en) CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF
WO2006036729A3 (en) USE OF TGF-β ANTAGONISTS TO LIMIT NEPHROTOXICITY OF IMMUNOSUPPRESSIVE AGENTS
Ferro et al. Cyclo‐Gly‐Pro, a cyclic dipeptide, attenuates nociceptive behaviour and inflammatory response in mice
Serata et al. Are 5‐HT3 antagonists effective in obsessive–compulsive disorder? A systematic review of literature
WO2007096396A3 (en) Methods for treating autoimmune or demyelinating diseases
MA30865B1 (fr) Utilisation de cyclosporines modifiees
WO2007034490A3 (en) Diastereomeric peptides for modulating t cell immunity
Segarra Medrano et al. Efficacy and safety of combined cyclosporin A and mycophenolate mofetil therapy in patients with cyclosporin-resistant focal segmental glomerulosclerosis
Pelayo et al. Localisation and activation of the neurokinin 1 receptor in the enteric nervous system of the mouse distal colon
Srivastava et al. Current Update on Evidence based Literature ofTofisopam
HK1072012A1 (en) 5-ht4 receptor antagonists for the treatment of heart failure
Stenberg et al. Predictors and mediators of add-on mirtazapine-induced cognitive enhancement in schizophrenia–a path model investigation
MA32129B1 (fr) Cyclosporine non immunosuppressive pour le traitement de la dystrophie musculaire
Smyth et al. Coincident membranous glomerulonephritis and chronic inflammatory demyelinating polyradiculoneuropathy: questioning the autoimmunity hypothesis
Huang et al. Taiwan Dementia Treatment Guideline.
CY1114268T1 (el) Συνδυασμος αναστολης blys και μυκοφαινολικης μοφετιλης για θεραπεια αυτοανοσης ασθενειας
Koh et al. Early aggressive immunotherapy improves functional outcome in chronic immune sensory polyradiculopathy
EA200802354A1 (ru) Средство и способ повышения половой активности человека
US8557959B2 (en) Allele and isotope-specific intervention on MHC class II molecules associated with autoimmune diseases by means of peptides